CorMedix (NASDAQ: CRMD) reported Q3 EPS of ($0.05), $0.06 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $11.5 million versus the consensus estimate of $10.35 million.

For earnings history and earnings-related data on CorMedix (CRMD) click here.